News

Delayed-release dimethyl fumarate (Tecfidera) was recently approved for patients with relapsing-remitting multiple sclerosis (RRMS), although the mechanisms by which the drug exerts its action were not fully understood. A new study from the University Hospital Münster, Germany, shows that dimethyl fumarate alters the balance between subpopulations of T-cells to promote…

The National Multiple Sclerosis Society in the U.S. has awarded a new grant to a University College London (UCL)  research team to continue work into compounds with the potential to act as neuroprotective therapies for degenerative diseases like multiple sclerosis (MS). The financial support comes through the Society’s business-oriented subsidiary, the Fast Forward venture.

Amarantus Bioscience Holdings, Inc., and Avant Diagnostics recently announced they have entered into a Letter of Intent (LOI) to merge Amarantus Diagnostics, an Amarantus-owned subsidiary, into Avant Diagnostics. The merger is being undertaken to advance the commercial development of diagnostic assets in the fields of oncology and neurology, including those specifically…

In a new study, researchers at the Scripps Research Institute (TSRI) uncovered the molecular mechanisms behind the perceived clinical efficacy of a specific drug type, sphingosine 1-phosphate receptor 1 (S1PR1) agonists, to diminish the harmful immune response that leads to autoimmunity in multiple sclerosis (MS) and other diseases, while still preserving the immune system’s…

Clinical trials suggest that hematopoietic stem cell transplantation (HSCT), a common treatment for bone marrow and blood cancers, could also help people with multiple sclerosis (MS). The technique involves harvesting new, undeveloped blood or bone marrow (hematopoietic) cells, typically from the person affected with the disease (autologous). The goal is to…

Barrett-Jackson, an Arizona-based auction company specializing in the auction of antique and classic automobiles,  has announced that the National Multiple Sclerosis Society will be among the nonprofits supported through its 45th Anniversary auction of custom vehicles. The company has donated over $84.6 million to charities since 1971. The anniversary auction, which includes a number of…

EMD Serono, the North American biopharmaceutical business arm of Merck, announced it has gained exclusive rights over Rebif (interferon beta-1a) in the United States. Rebif  is a treatment for relapsing forms of multiple sclerosis (MS). Rebif, an approved drug, is used to decrease the frequency of MS relapses and delay the occurrence of…

A recent BBC Panorama program titled “Can you stop my Multiple Sclerosis?” featured a ground-breaking treatment for select patients with multiple sclerosis (MS) that has been developed at Sheffield Teaching Hospitals in the United Kingdom. The program tells the stories of four patients, each with a diagnosis of relapsing-remitting MS (RRMS), who underwent the…

A study from the University of Technology Dresden, in Germany, reported on attitudes toward the adoption of electronic health (eHealth) solutions among clinicians in neurological practices, and their opinions on the those systems’ requirements and  potential benefits in the field of multiple sclerosis (MS). The study, “Designing an…

The U.S. Food and Drug Administration (FDA) will hold a one-day public hearing on four recent draft guidelines regarding the regulation of human cells, tissues, or cellular or tissue-based products (HCT/Ps). Critics of the proposed regulations warn that they curtail the medical use of autologous cell therapy and biologics, and their future potential…

A Colombian study reported finding an increased risk of multiple sclerosis (MS) associated with a particular allele, or gene variant, in a group of patients from the Colombian capital, Bogotá. The study also found a protective allele — HLA-DRB1*14 — that might explain the low rates of MS observed throughout the…

The Tisch MS Research Center of New York (Tisch MSRCNY) recently announced that its stem cell-based therapy as a potential treatment for multiple sclerosis (MS) will move into Phase 2 clinical testing after encouraging results in a Phase 1 trial, and on the advice of  the U.S. Food and Drug…

Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what is Anti-LINGO-1? According to the MS Society, Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…

A team of researchers recently discovered two novel multiple sclerosis (MS)-associated genes that are regulated by vitamin D levels. The study, titled “The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells,” was published in the advanced online section of …

Dr. Richard Reynolds of Imperial College London spoke of the importance of philanthropy to research during a December 2015 visit from Nigel Furmston, a supporter of multiple sclerosis (MS) research, who came to the Hammersmith Campus to award the scientist and his team £50,000 to continue its work into disease development. Furmston, whose wife Sharon suffers from…

One of the teams participating in the 10th anniversary of the MS Melbourne Cycle, an annual biking challenge to raise money for MS Australia, has built a bicycle that as closely as possible replicates the physical difficulties and discomforts that typify multiple sclerosis (MS). A collaboration between the company Grey Australia, paralympic athlete Carol…

The Multiple Sclerosis Society of Canada recently published a report documenting and summarizing the most important developments in multiple sclerosis (MS) research during 2015. In early 2015, a Society-funded clinical trial was initiated to study the potential abilities of mesenchymal stem cells (MSCs) to treat MS. The MEsenchymal Stem cell therapy…

A new study from The Weizmann Institute of Science, Israel, found that the inflammatory molecule CXCL12 promotes neuronal repair during spontaneous remission in mice with experimental autoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis (MS). The chemokine CXCL12 was previously thought to be a pro-inflammatory molecule only. But recent findings have shown…

Tiziana Life Sciences, plc, a biotechnology company specializing in drugs to treat immunological and oncological diseases,  recently announced its intent to further develop foralumab, a fully human monoclonal antibody targeting the CD3 receptor. This approach, aiming to modulate the immune T cell response and achieve immunosuppression, is well-validated and has the potential to…

IQuity Labs, which specializes in diagnostic tests for autoimmune and other diseases, recently announced that it has received $2 million in seed funding to support the launch of its test panels, diagnostic tests designed to confirm the presence or absence of disease at the very onset of symptoms. The first to…

A Canadian study showed that child-onset multiple sclerosis (MS) is characterized by increased functional connectivity within the brain, most likely a compensatory effect to preserve function and protect against physical disability. The study, titled “Alterations in Functional and Structural Connectivity in Pediatric-Onset Multiple Sclerosis,“ was published in the journal …

New research evaluating fingolimod’s clinical efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS) largely supported its use, finding that the oral drug’s efficacy in a real-world setting was comparable to results observed in Phase 3 clinical studies. The research article, “Efficacy and Safety of Fingolimod in an Unselected…

A new source of stem cells, the mesenchymal stem cells (MSCs) isolated from the human periodontal ligament (hPDLSCs), offers a potential treatment capable of halting multiple sclerosis (MS) progression. The study, “Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis,” was published…

In a recent study, a team of researchers argued that, contrary to what has been proposed, subclinical Bordetella pertussis colonization is an important cause of multiple sclerosis (MS). The study, “The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis,” was published in the journal…

The 5th International Symposium on Gait and Balance in MS, held in September 2015, focused entirely on research into balance and its loss in multiple sclerosis (MS). Nearly 100 clinicians, scientists, engineers, and others sharing this research interest gathered to discuss why and how often MS patients fall, and how to…

Ralph H. Benedict, PhD, professor of neurology at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB), has been selected by The International Neuropsychological Society (INS) to receive the 2016 INS Mid-Career Award, also called Arthur Benton Award, for his work on…

MedChew Rx, by AXIM Biotechnology, the world’s first patented cannabinoid release chewing gum for pain and spasticity in multiple sclerosis (MS), is moving into clinical testing. If all goes well, the company plans for a global release date of 2017. Medical cannabis is believed to have considerable promise as a therapy for…

A new randomized and controlled trial is recruiting multiple sclerosis (MS) patients to investigate the effect of a mindfulness-based telemedicine intervention program on patients and their caregivers. The clinical study’s protocol was recently published in the journal Trials, titled “A telemedicine meditation intervention for people with multiple sclerosis…

In a new study, researchers found that additives common to processed foods can damage the tight junctions that protect the intestinal mucosa, and which are essential to the intestinal tolerance and immunity balance that works to prevent autoimmune diseases such as multiple sclerosis (MS). The article, titled “Changes in…

Teva Pharmaceutical Industries Ltd. and Active Biotech have discontinued the use of higher doses of the drug laquinimod in two ongoing multiple sclerosis (MS) studies. The decision was based on a recommendation by the Data Monitoring Committee (DMC) that is supervising the clinical trials after cardiovascular events, none of which were fatal,…